Clinical trials: Healthy Male Subjects
Healthy
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080
The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 765080 in healthy male subjects following intravenous administration of single rising doses.
- Trial name
- NCT04666922
- Testing
- BI 765080
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Invasive Aspergillosis
Single Ascending Oral Dose Study of F901318
Double blind, placebo controlled, ascending single oral dose, sequential group study. Forty subjects will complete the study in 5 cohorts (Groups A to E), each group consisting of 8 subjects.
- Trial name
- NCT02394483
- Testing
- F901318 safety, F901318 tolerability, F901318 pharmacokinetics
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy Subjects
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of [14C]-SKI-606 in healthy male subjects.
- Trial name
- NCT00757341
- Testing
- SKI-606
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
A Study of LY3214996 in Healthy Participants
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996.
- Trial name
- NCT04033341
- Testing
- LY3214996, [14C]-LY3214996
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers
This clinical trial will include two parts, i.e., Part A and Part B. The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations…
- Trial name
- NCT06840769
- Testing
- Fosnetupitant 235 mg solution, Akynzeo solution
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Healthy Volunteer
A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
This 2-arm, open-label, non-randomized study will investigate the absolute bioavailability, pharmacokinetics, mass balance, and routes of elimination of GDC-0032 as well as its safety in healthy volunteers.
- Trial name
- NCT01967966
- Testing
- GDC-0032
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants.
- Trial name
- NCT03405441
- Testing
- JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2, JNJ-55375515 Dose Level 3
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type2 Diabetes
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg
A randomized, open-label, multiple dosing, three treatment, three period, two sequence clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and glimepiride 4 mg after oral…
- Trial name
- NCT02954822
- Testing
- Evogliptin→Evogliptin+Glimepiride→Glimepiride, Glimepiride→Evogliptin→Evogliptin+Glimepiride
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Atherosclerosis
A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men
This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients
- Trial name
- NCT00551317
- Testing
- Darapladib (SB480848)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers
This is a phase I, open label, healthy volunteers, ADME study with single oral administration of [14C]-AZD4205.
- Trial name
- NCT04225208
- Testing
- [14C]-AZD4205, single 50 mg oral dose administrated on day 1
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
HIV Infection, Infection, Human Immunodeficiency Virus
Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
To evaluate the single dose relative bioavailability of GSK1265744 10mg administered in either oral solution fasted, two 5mg tablets fasted, or two 5mg tablets following a moderate meal.
- Trial name
- NCT00812318
- Testing
- GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Asthma
Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633
This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.
- Trial name
- NCT01086462
- Testing
- GSK2239633
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study
The purpose of this study is to assess the safety, tolerability pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and how it is removed from the body over time) and pharmacodynamics…
- Trial name
- NCT01105780
- Testing
- JNJ-41443532
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Subjects
A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men
This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the pharmacokinetics of 2 different formulations of ACT-709478 in healthy male participants.
- Trial name
- NCT04123288
- Testing
- ACT-709478
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Lymphoblastic Leukemia
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
The primary objective of this study is to determine whether the test product, mercaptopurine oral 100 mg/5 mL suspension, and the reference product, Purinethol® 50 mg tablets are bioequivalent.
- Trial name
- NCT01697020
- Testing
- Mercaptopurine 20mg/ml oral suspension, Mercaptopurine 50mg tablet
- Where
- South Africa
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Nova Laboratories Limited
Acute Kidney Injury
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.
- Trial name
- NCT02460146
- Testing
- CXA-10
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
Healthy
Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components
The objective of the current study is to establish the bioequivalence of linagliptin/ pioglitazone fixed dose combination tablet compared to single tablets of linagliptin and pioglitazone administered together.
- Trial name
- NCT01276327
- Testing
- Linagliptin + Pioglitazone, Linagliptin/Pioglitazone
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects (HS)
Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
A Phase 1, Open-label Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion in Healthy Male Subjects
- Trial name
- NCT07247942
- Testing
- zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Healthy
Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers
Human mass-balance studies with radiolabelled study drug are needed to evaluate the amount of drug that is recovered over time via different elimination routes of the body, i.e., whole blood, blood cells, plasma, urine, feces…
- Trial name
- NCT02142127
- Testing
- 14C-labelled GFT505 120 mg
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy
Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects
To investigate bioavailability of BI 187004 and of metformin after concomitant multiple oral administration of 240 mg BI 187004 q.d. and 1000 mg metformin b.i.d. in comparison to BI 187004 and metformin given alone.
- Trial name
- NCT02109679
- Testing
- metformin, BI 187004
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim